Nucleic acid encoding gamma retinoic acid receptor fusion protein
AssigneesThe Salk Institute for Biological Studies, Sloan-Kettering Institute for Caneer Research
InventorsFumimaro Takaku, Takashi Ishikawa, Michio Imawari, Ronald Mark Evans, Kazuhiko Umesono
Life of this patent
Estimating the term…
Abstract
A novel gamma retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid pGEM-hRARγ, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera contain at least one functional domain from the new gamma retinoic acid receptor.
Claims6
A nucleic acid encoding a chimeric receptor having an N-terminus domain, a DNA-binding domain, and a ligand-binding domain,
- wherein the N-terminus domain of said chimeric receptor is obtained from the N-terminus domain of retinoic acid receptor-alpha (RARα), retinoic acid receptor-beta (RARβ), retinoic acid receptor-gamma (RARγ), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone receptor (PR), estrogen receptor (ER), vitamin D3 receptor (VDR), thyroid receptor (TR), the v-erb-A receptor, or the Drosophila E75 receptor,
- wherein the DNA-binding domain of said chimeric receptor is obtained from the DNA-binding domain of RARα, RARβ, RARγ, GR, MR, PR, ER, VDR, TR, the v-erb-A receptor, or the Drosophila E75 receptor, and
- wherein the ligand-binding domain of said chimeric receptor is obtained from the ligand-binding domain of RARα, RARβ, RARγ, GR, MR, PR, ER, ERR1, ERR2, VDR, TR, the v-erb-A receptor, or the Drosophila E75 receptor,
- wherein at least one of the domains of said chimeric receptor comprises a contiguous portion unique to RARγ selected from the group consisting of a nucleotide sequence encoding amino acid residues 1–89 of hRARγ set forth in FIG. 1, a nucleotide sequence encoding an amino acid sequence having greater than 97% identity with amino acid residues 90–155 of hRARγ set forth in FIG. 1, and a nucleotide sequence encoding an amino acid sequence having greater than 90% identity with amino acid residues 202–421 of hRARγ set forth in FIG. 1, and
- wherein said chimeric receptor has at least 5% of the DNA-binding, the transcription-activating activity, and/or the ligand-binding activity of RARγ.
A nucleic acid encoding a chimeric receptor having an N-terminus domain, a DNA-binding domain, and a ligand-binding domain,
- wherein the N-terminus domain of said chimeric receptor is obtained from the N-terminus domain of retinoic acid receptor-alpha (RARα), retinoic acid receptor-beta (RARβ), retinoic acid receptor-gamma (RARγ), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone receptor (PR), estrogen receptor (ER), vitamin D3 receptor (VDR), thyroid receptor (TR), the v-erb-A receptor, or the Drosophila E75 receptor,
- wherein the DNA-binding domain of said chimeric receptor is obtained from the DNA-binding domain of RARα, RARβ, RARγ, GR, MR, PR, ER, VDR, TR, the v-erb-A receptor, or the Drosophila E75 receptor, and
- wherein the ligand-binding domain of said chimeric receptor is obtained from the ligand-binding domain of RARα, RARβ, RARγ, GR, MR, PR, ER, VDR, TR, the v-erb-A receptor, or the Drosophila E75 receptor,
- wherein at least one of the domains of said chimeric receptor comprises a contiguous portion unique to RARγ selected from the group consisting of a nucleotide sequence encoding amino acid residues 1–89 of hRARγ set forth in FIG. 1, a nucleotide sequence encoding amino acid residues 90–155 of hRARγ set forth in FIG. 1, and a nucleotide sequence encoding amino acid residues 202–421 of hRARγ set forth in FIG. 1, and
- wherein said chimeric receptor has at least 5% of the DNA-binding, the transcription-activating activity and/or the ligand-binding activity of RARγ.
Dependencies are inferred from the claim text.